A RETROSPECTIVE, MOLECULAR STUDY OF EGFR AND ALK MUTATIONS IN NON SMALL CELL LUNG CANCER PATIENTS

Abstract

Background: Epidermal growth factor receptor EGFR/ALK mutations are the strongest response predictors to EGFR tyrosine kinase inhibitors (TKI) and ALK inhibitor respectively, but knowledge of the EGFR/ALK mutation frequency on lung adenocarcinoma is still limited.

Methodology: Our study is a retrospective study of the metastatic non small cell lung cancer patients harboring EGFR/ALK receptors. A total of 94 metastatic non small cell lung carcinoma patients data were evaluated, out of which 74 patient’s EGFR&ALK mutation status was known.

Results: All of the patient’s data evaluated in this study were in the age group of 30-74.Total 74 patient’s EGFR &ALK mutation status was known, out of which 34.2% were positive for EGFR and 4% for ALK respectively. In EGFR positive group 62.96%were male and 37.04% were female. Among males patients 34% were positive for EGFR as compared to 42% of EGFR Positive female patients.

Conclusion: Efforts to obtain tissue samples should be encouraged for EGFR&ALK mutation testing in non small cell lung carcinoma patients to provide a molecular basis to treat patients with available targeted therapy.